

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2007-001049-16/ Novartis Protocol ID CLAF237AGB01

*A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes.*

Trial CLAF237AGB01 was cancelled with no patient enrollment and as such, no results will be reported.